Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Decitabine Compared with Treatment Choice in DACO-016 Phase III Trial
Jörg Tomeczkowski(Janssen (Germany)), Christoph Tapprich(Johnson & Johnson (Germany)), Pushpike Thilakarathne(Janssen (Belgium)), Joris Diels(Janssen (Belgium)), Andreas Güntert(King's College London), L. Xiu(Janssen (United States))
Cited by 0
Related Papers
Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease
|Archives of General Psychiatry|2010|402
Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings
|Bone Marrow Transplantation|2005|81
Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes
|Experimental Hematology|2008|58
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
|Current Medical Research and Opinion|2021|49
Burden of illness of follicular lymphoma and marginal zone lymphoma
|Annals of Hematology|2018|32